In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines
This article was originally published in Start Up
Executive Summary
With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.